Latest News

NICE recommends Teva’s Cinqaero to treat severe eosinophilic asthma

The UK National Institute for Health and Care Excellence (NICE) has recommended Teva Pharmaceutical Industries’ Cinqaero (reslizumab) for the treatment of patients with severe eosinophilic...

NICE recommends Teva’s Cinqaero to treat severe eosinophilic asthma

Deals this week: Hugel, Guangdong Zhongsheng Pharmaceutical, Valeant Pharmaceuticals International

South Korean pharmaceutical company Hugel has announced the private placement of 985,217 common stock shares priced at KRW360,001.9 ($316.2) a share to raise KRW354.68bn ($311.52m) in gross...

Deals this week: Hugel, Guangdong Zhongsheng Pharmaceutical, Valeant Pharmaceuticals International

Ablynx and Sanofi collaborate for nanobody-based inflammatory disease treatments

Belgian biopharmaceutical company Ablynx has entered a research collaboration and global exclusive licensing agreement with French firm Sanofi to develop and commercialise...

Ablynx and Sanofi collaborate for nanobody-based inflammatory disease treatments

M&As this week: Northeast Pharmaceutical Group, Principia SGR, Commelina

Chinese pharmaceutical company Northeast Pharmaceutical Group plans to acquire 60% stake in a medicine company based in Dandong, China, through its subsidiary for CNY3.9m...

M&As this week: Northeast Pharmaceutical Group, Principia SGR, Commelina

Elsalys Biotech and DKFZ collaborate to develop ELB021 in B-Cell leukaemia

Elsalys Biotech has entered a preclinical collaboration with German cancer research institute DKFZ to initiate the development of ELB021 in B-Cell leukaemia, under European Union (EU)...

Elsalys Biotech and DKFZ collaborate to develop ELB021 in B-Cell leukaemia

Gilead’s Vosevi receives FDA approval for re-treatment of chronic HCV

Gilead’s Vosevi receives FDA approval for re-treatment of chronic HCV

GSK to invest additional £140m at UK manufacturing sites

GlaxoSmithKline (GSK) is set to invest more than £140m at its production facilities in the UK to improve the efficiency and competitiveness of its manufacturing...

GSK to invest additional £140m at UK manufacturing sites

Takeda and Prana to research neurodegeneration treatment for Parkinson's disease

Takeda Pharmaceuticals International has entered a new research collaboration to study the ability of Prana Biotechnology’s investigational movement disorders compound, PBT434, to slow down...

Takeda and Prana to research neurodegeneration treatment for Parkinson's disease

Valeant to sell Obagi medical products business for $190m

Valeant Pharmaceuticals International has entered an agreement through certain affiliates to divest its Obagi Medical Products business to Haitong International Zhonghua Finance Acquisition...

Valeant to sell Obagi medical products business for $190m

Research team discovers epithelial cells in eyes can prevent spread of Ebola

Research team discovers epithelial cells in eyes can prevent spread of Ebola

UDG Healthcare to acquire Cambridge BioMarketing for up to $35m

International healthcare services provider UDG Healthcare has agreed to acquire US-based healthcare communications business Cambridge BioMarketing for a total consideration of up to...

UDG Healthcare to acquire Cambridge BioMarketing for up to $35m

FDA asks for additional data to approve Evenity in US

Pharmaceutical companies Amgen and UCB have received a Complete Response Letter from the US Food and Drug Administration (FDA) for Evenity, a treatment for postmenopausal women with...

FDA asks for additional data to approve Evenity in US

Roche’s Ocrevus receives TGA approval for RMS and PPMS treatment in Australia

Roche’s Ocrevus receives TGA approval for RMS and PPMS treatment in Australia

Janssen Biotech’s Tremfya receives FDA approval for plaque psoriasis treatment

The US Food and Drug Administration (FDA) has granted approval for Janssen Biotech’s Tremfya (guselkumab) to treat adults with moderate-to-severe plaque psoriasis who are candidates for...

Janssen Biotech’s Tremfya receives FDA approval for plaque psoriasis treatment

US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitis

US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitis

Emergent BioSolutions to buy Sanofi’s smallpox vaccine business for $125m

US-based Emergent BioSolutions has entered an agreement to buy the ACAM2000, smallpox vaccine business of French pharmaceutical company Sanofi for up to...

Emergent BioSolutions to buy Sanofi’s smallpox vaccine business for $125m

Deals this week: North China Pharmaceutical, Arena Pharmaceuticals, Enterome Bioscience

Chinese pharmaceutical company North China Pharmaceutical has announced the completion of a public offering of ten million short-term bonds to raise CNY1bn...

Deals this week: North China Pharmaceutical, Arena Pharmaceuticals, Enterome Bioscience

M&As this week: Sanofi, GE Healthcare, Medicure

Sanofi has announced plans to acquire US-based vaccines biotechnology company, Protein Sciences...

M&As this week: Sanofi, GE Healthcare, Medicure

BNF and BNFC launch new app for health and social care professionals

The British National Formulary (BNF) and the British National Formulary for children (BNFC) have launched a new faster and easily accessible app for healthcare...

BNF and BNFC launch new app for health and social care professionals

FDA recommends approval for Novartis’ CTL019 to treat r/r B-cell ALL

FDA recommends approval for Novartis’ CTL019 to treat r/r B-cell ALL

EMA validates Gilead Sciences’ marketing application for BIC/FTC/TAF combination

US biopharmaceutical company Gilead Sciences’ marketing authorisation application (MAA) for a fixed-dose drug combination to treat HIV-1 infection in adults has been fully validated and...

EMA validates Gilead Sciences’ marketing application for BIC/FTC/TAF combination
cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1460672566_rd1460672566_371857150_ap1460672566_1857678299_946450448